FRI0150 Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study

Abstract

BackgroundCertolizumab pegol (CZP) increased rates of remission and low disease activity (LDA) as an addition to non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) with long-standing, low/moderate disease activity (DA).1ObjectivesTo...